Analytical Data
-
Gene name
OX40 Ligand/TNFSF4
- Application
-
Species
Cynomolgus; Rhesus Macaque
-
Source
HEK293
-
Tag
N-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A2K5TTN0
-
Expression Region
Q81-L213
-
Protein Length
Partial
-
Molecular Weight
25-38 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OX40 Ligand, also known as TNFSF4, is a pivotal member of the tumor necrosis factor (TNF) superfamily that plays a crucial role in regulating immune responses, particularly in T-cell activation and survival. It is expressed primarily on antigen-presenting cells and binds to the OX40 receptor on T cells, facilitating their proliferation, differentiation, and long-term persistence. The OX40/OX40L interaction has emerged as a significant target in immunotherapy, particularly in enhancing anti-tumor immune responses. Understanding the structural and functional dynamics of the OX40 ligand, and developing recombinant forms of this protein, has garnered substantial interest in both basic and clinical research. Recombinant OX40L proteins are being utilized to explore their potential in cancer treatments and autoimmune diseases by modulating T-cell activity. Additionally, the functional characterization of OX40L could provide insights into its role in various pathological conditions, paving the way for novel therapeutic strategies. As such, the study of OX40 Ligand/TNFSF4 not only expands the knowledge of immune modulation but also holds promise for innovative approaches in targeted therapies for cancer and other immune-related disorders.
